Company patents
Merus N.V.
Merus N.V. demonstrates a clear focus on Peptides & Proteins, accounting for 93.2% of its portfolio, with a significant surge in 2024 (YoY +80.0%) followed by a sharp decline in 2025 (YoY -72.2%) and so far in 2026 (YoY -70.0%), indicating a potential shift in patenting strategy or a consolidation of its core intellectual property. Surprisingly, despite being a pharma company, there was a brief but intense focus on Animal Husbandry / Fishing in 2024, showing a 100.0% YoY growth, before completely ceasing in 2025 and 2026, suggesting an exploratory or short-lived diversification that has since been deprioritized.
Patent Trend by Technology Area
Yearly patent publications since 2023
Product themes
Product-level themes inferred from filings since 2023, with category chips showing where each theme appears. Select a theme to filter the patents below.
74 US filings (since 2023) · 7 categories · 12 themes
Design and modification of antibodies or antibody-derived fragments for targeted therapeutic intervention, including bispecific formats, Fc region modifications, and activatable constructs.
Design and engineering of proteins or peptides to directly modulate immune responses, including enhancing antigen presentation, suppressing inflammation, or activating specific immune cell types.
Methods and compositions for identifying, quantifying, or characterizing specific biological molecules (e.g., nucleic acids, proteins, metabolites, antibodies) or microbial species, often for diagnostic, prognostic, or quality control applications.
Development and application of therapeutic proteins or peptides produced through recombinant DNA technology, including fusion proteins and modified growth factors.
Therapeutic interventions that target immune checkpoint pathways to either enhance or suppress immune responses, often used in cancer immunotherapy or autoimmune diseases.
Development of therapeutic approaches involving the genetic modification of cells (e.g., T cells, stem cells, macrophages) or the use of viral/non-viral vectors to deliver genetic material for disease treatment.
Therapeutic approaches involving the use of living cells, often genetically modified or ex vivo activated, to treat diseases, particularly cancer, by modulating immune responses or replacing damaged cells.
Methods and systems for the efficient and scalable production, purification, and formulation of proteins and peptides, including fermentation, chromatography, and cell-based expression systems.
Identification and measurement of specific nucleic acid sequences (DNA, RNA), their expression levels, or epigenetic modifications (e.g., methylation) as indicators for disease presence, progression, risk, or treatment response.
Design and synthesis of acyclic or carbocyclic organic compounds that selectively modulate specific biological targets or pathways for the treatment of diseases.
Modification of protein or peptide sequences, structures, or post-translational modifications (e.g., glycosylation, lipidation) to enhance their stability, solubility, delivery, or therapeutic efficacy.
Assays leveraging CRISPR-Cas systems (e.g., Cas12, Cas13) for highly specific and sensitive detection of target nucleic acids, often involving collateral cleavage activity or reporter molecules.
Patents
Showing 1-10 of 95